1 |
Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 2013;9:141-153.
DOI
|
2 |
Nakaoka H, Cui T, Tajima A, et al. A systems genetics approach provides a bridge from discovered genetic variants to biological pathways in rheumatoid arthritis. PLoS One 2011;6:e25389.
DOI
|
3 |
Sakaguchi N, Takahashi T, Hata H, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003;426:454-460.
DOI
ScienceOn
|
4 |
Xing H, McDonagh PD, Bienkowska J, et al. Causal modeling using network ensemble simulations of genetic and gene expression data predicts genes involved in rheumatoid arthritis. PLoS Comput Biol 2011;7:e1001105.
DOI
ScienceOn
|
5 |
Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford) 2011;50:437-449.
DOI
ScienceOn
|
6 |
Yoon HJ, You S, Yoo SA, et al. NF-AT5 is a critical regulator of inf lammatory arthritis. Arthritis Rheum 2011;63:1843-1852.
DOI
ScienceOn
|
7 |
Wu G, Zhu L, Dent JE, Nardini C. A comprehensive molecular interaction map for rheumatoid arthritis. PLoS One 2010;5:e10137.
DOI
ScienceOn
|
8 |
Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610-2615.
DOI
ScienceOn
|
9 |
Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-723.
DOI
ScienceOn
|
10 |
Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951-2962.
DOI
ScienceOn
|
11 |
Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-1503.
DOI
ScienceOn
|
12 |
Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA. Association of a gene expression prof ile from whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis 2008;67:1069-1075.
DOI
ScienceOn
|
13 |
Petri M, Singh S, Tesfasyone H, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009;18:980-989.
DOI
|
14 |
Chaussabel D, Quinn C, Shen J, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008;29:150-164.
DOI
ScienceOn
|
15 |
Chiche L, Jourde-Chiche N, Whalen E, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol 2014;66:1583-1595.
DOI
ScienceOn
|
16 |
Siddani BR, Pochineni LP, Palanisamy M. Candidate gene identification for systemic lupus erythematosus using network centrality measures and gene ontology. PLoS One 2013;8:e81766.
DOI
|
17 |
Pflegerl P, Vesely P, Hantusch B, et al. Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci U S A 2009;106:20423-20428.
DOI
ScienceOn
|
18 |
Jacob CO, Eisenstein M, Dinauer MC, et al. Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase. Proc Natl Acad Sci U S A 2012;109:E59-E67.
DOI
|
19 |
Jeffries MA, Dozmorov M, Tang Y, Merrill JT, Wren JD, Sawalha AH. Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics 2011;6:593-601.
DOI
|
20 |
Romzova M, Hohenadel D, Kolostova K, et al. NFkappaB and its inhibitor IkappaB in relation to type 2 diabetes and its microvascular and atherosclerotic complications. Hum Immunol 2006;67:706-713.
DOI
ScienceOn
|
21 |
Salvador JM, Hollander MC, Nguyen AT, et al. Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity 2002;16:499-508.
DOI
ScienceOn
|
22 |
Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013;110:3507-3512.
DOI
ScienceOn
|
23 |
Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME. Lupus nephritis: a critical review. Autoimmun Rev 2012;12:174-194.
DOI
ScienceOn
|
24 |
Berthier CC, Bethunaickan R, Gonzalez-Rivera T, et al. Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol 2012;189:988-1001.
DOI
ScienceOn
|
25 |
Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-1390.
DOI
ScienceOn
|
26 |
Zhao J, Chen J, Yang TH, Holme P. Insights into the pathogenesis of axial spondyloarthropathy from network and pathway analysis. BMC Syst Biol 2012;6 Suppl 1:S4.
|
27 |
Sharma SM, Choi D, Planck SR, et al. Insights in to the pathogenesis of axial spondyloarthropathy based on gene expression profiles. Arthritis Res Ther 2009;11:R168.
DOI
ScienceOn
|
28 |
Tam LS, Gu J, Yu D. Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 2010;6:399-405.
DOI
|
29 |
Delany AM, Hankenson KD. Thrombospondin-2 and SPARC/osteonectin are critical regulators of bone remodeling. J Cell Commun Signal 2009;3:227-238.
DOI
ScienceOn
|
30 |
Machado do Reis L, Kessler CB, Adams DJ, Lorenzo J, Jorgetti V, Delany AM. Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice. Bone 2008;43:264-273.
DOI
ScienceOn
|
31 |
Gu J, Marker-Hermann E, Baeten D, et al. A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients. Rheumatology (Oxford) 2002;41:759-766.
DOI
ScienceOn
|
32 |
Smith JA, Barnes MD, Hong D, DeLay ML, Inman RD, Colbert RA. Gene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferon-gamma dysregulation. Arthritis Rheum 2008;58:1640-1649.
DOI
ScienceOn
|
33 |
Duan R, Leo P, Bradbury L, Brown MA, Thomas G. Gene expression prof iling reveals a downregulation in immune-associated genes in patients with AS. Ann Rheum Dis 2010;69:1724-1729.
DOI
ScienceOn
|
34 |
Gu J, Wei YL, Wei JC, et al. Identification of RGS1 as a candidate biomarker for undifferentiated spondylarthritis by genome-wide expression prof iling and real-time polymerase chain reaction. Arthritis Rheum 2009;60:3269-3279.
DOI
ScienceOn
|
35 |
Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 2008;321:263-266.
DOI
ScienceOn
|
36 |
Assassi S, Reveille JD, Arnett FC, et al. Whole-blood gene expression prof iling in ankylosing spondylitis shows upregulation of toll-like receptor 4 and 5. J Rheumatol 2011;38:87-98.
DOI
|
37 |
Haroon N, Tsui FW, O'Shea FD, et al. From gene expression to serum proteins: biomarker discovery in ankylosing spondylitis. Ann Rheum Dis 2010;69:297-300.
DOI
ScienceOn
|
38 |
Gu J, Rihl M, Marker-Hermann E, et al. Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profiles. J Rheumatol 2002;29:2159-2164.
|
39 |
Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012;148:1293-1307.
DOI
ScienceOn
|
40 |
Craig J. Complex diseases: research and applications. Nat Educ 2008;1:184.
|
41 |
Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011;12:56-68.
DOI
ScienceOn
|
42 |
Ku CS, Loy EY, Pawitan Y, Chia KS. The pursuit of genome-wide association studies: where are we now? J Hum Genet 2010;55:195-206.
DOI
ScienceOn
|
43 |
Ormond KE, Wheeler MT, Hudgins L, et al. Challenges in the clinical application of whole-genome sequencing. Lancet 2010;375:1749-1751.
DOI
ScienceOn
|
44 |
Wang J, Zhang Y, Marian C, Ressom HW. Identification of aberrant pathways and network activities from high-throughput data. Brief Bioinform 2012;13:406-419.
DOI
|
45 |
Altman RB. Translational bioinformatics: linking the molecular world to the clinical world. Clin Pharmacol Ther 2012;91:994-1000.
DOI
|
46 |
Likic VA, McConville MJ, Lithgow T, Bacic A. Systems biology: the next frontier for bioinformatics. Adv Bioinformatics 2010;2010:268925.
|
47 |
Hartwell LH, Hopfield JJ, Leibler S, Murray AW. From molecular to modular cell biology. Nature 1999;402(6761 Suppl):C47-C52.
DOI
ScienceOn
|
48 |
Koutsogiannouli E, Papavassiliou AG, Papanikolaou NA. Complexity in cancer biology: is systems biology the answer? Cancer Med 2013;2:164-177.
DOI
|
49 |
MacLellan WR, Wang Y, Lusis AJ. Systems-based approaches to cardiovascular disease. Nat Rev Cardiol 2012;9:172-184.
DOI
|
50 |
Furlong LI. Human diseases through the lens of network biology. Trends Genet 2013;29:150-159.
DOI
ScienceOn
|
51 |
You S, Cho CS, Lee I, Hood L, Hwang D, Kim WU. A systems approach to rheumatoid arthritis. PLoS One 2012;7:e51508.
DOI
ScienceOn
|
52 |
You S, Yoo SA, Choi S, et al. Identification of key regu lators for the migration and invasion of rheumatoid synoviocytes through a systems approach. Proc Natl Acad Sci U S A 2014;111:550-555.
DOI
ScienceOn
|
53 |
Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The human disease network. Proc Natl Acad Sci U S A 2007;104:8685-8690.
DOI
ScienceOn
|
54 |
Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M. Drug-target network. Nat Biotechnol 2007;25:1119-1126.
DOI
ScienceOn
|
55 |
Bauer-Mehren A, Bundschus M, Rautschka M, Mayer MA, Sanz F, Furlong LI. Gene-disease network analysis reveals functional modules in mendelian, complex and environmental diseases. PLoS One 2011;6:e20284.
DOI
|
56 |
Suthram S, Dudley JT, Chiang AP, Chen R, Hastie TJ, Butte AJ. Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets. PLoS Comput Biol 2010;6:e1000662.
DOI
ScienceOn
|
57 |
Emig D, Ivliev A, Pustovalova O, et al. Drug target prediction and repositioning using an integrated network-based approach. PLoS One 2013;8:e60618.
DOI
|
58 |
International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004;431:931-945.
DOI
ScienceOn
|
59 |
Stumpf MP, Thorne T, de Silva E, et al. Estimating the size of the human interactome. Proc Natl Acad Sci U S A 2008;105:6959-6964.
DOI
ScienceOn
|
60 |
Venkatesan K, Rual JF, Vazquez A, et al. An empirical framework for binary interactome mapping. Nat Methods 2009;6:83-90.
DOI
ScienceOn
|
61 |
Jensen ON. Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. Curr Opin Chem Biol 2004;8:33-41.
DOI
ScienceOn
|
62 |
Altelaar AF, Munoz J, Heck AJ. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat Rev Genet 2013;14:35-48.
DOI
|
63 |
Chiche L, Jourde-Chiche N, Pascual V, Chaussabel D. Current perspectives on systems immunology approaches to rheumatic diseases. Arthritis Rheum 2013;65:1407-1417.
DOI
ScienceOn
|
64 |
Sirota M, Butte AJ. The role of bioinformatics in studying rheumatic and autoimmune disorders. Nat Rev Rheumatol 2011;7:489-494.
DOI
|
65 |
Altman RB. Introduction to translational bioinformatics collection. PLoS Comput Biol 2012;8:e1002796.
DOI
ScienceOn
|
66 |
Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-911.
DOI
ScienceOn
|
67 |
Moelants EA, Mortier A, Van Damme J, Proost P. Regulation of TNF-alpha with a focus on rheumatoid arthritis. Immunol Cell Biol 2013;91:393-401.
DOI
ScienceOn
|
68 |
Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
DOI
ScienceOn
|
69 |
Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009;11 Suppl 1:S1.
DOI
ScienceOn
|
70 |
Tanaka Y. Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis 2013;72 Suppl 2:ii124-ii127.
DOI
|
71 |
Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-259.
DOI
ScienceOn
|
72 |
Prince FH, Bykerk VP, Shadick NA, et al. Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther 2012;14:R68.
DOI
ScienceOn
|
73 |
Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011;70:315-319.
DOI
ScienceOn
|
74 |
Aguilar-Lozano L, Castillo-Ortiz JD, Vargas-Serafin C, et al. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. J Rheumatol 2013;40:1069-1073.
DOI
ScienceOn
|
75 |
Toonen EJ, Barrera P, Radstake TR, et al. Gene expression profiling in rheumatoid arthritis: current concepts and future directions. Ann Rheum Dis 2008;67:1663-1669.
DOI
ScienceOn
|
76 |
Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-1602.
DOI
ScienceOn
|
77 |
Chuang HY, Hofree M, Ideker T. A decade of systems biology. Annu Rev Cell Dev Biol 2010;26:721-744.
DOI
ScienceOn
|
78 |
Sarkar IN, Butte AJ, Lussier YA, Tarczy-Hornoch P, Ohno-Machado L. Translational bioinformatics: linking knowledge across biological and clinical realms. J Am Med Inform Assoc 2011;18:354-357.
DOI
ScienceOn
|
79 |
Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther 2013;93:335-341.
DOI
ScienceOn
|
80 |
Finckh A, Simard JF, Gabay C, Guerne PA; SCQM physicians. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:746-752.
DOI
ScienceOn
|
81 |
Keystone E, Burmester GR, Furie R, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2008;59:785-793.
DOI
ScienceOn
|
82 |
Liu Z, Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med 2012;18:871-882.
DOI
ScienceOn
|
83 |
Laukens D, Peeters H, Cruyssen BV, et al. Altered gut transcriptome in spondyloarthropathy. Ann Rheum Dis 2006;65:1293-1300.
DOI
ScienceOn
|
84 |
Landolt-Marticorena C, Bonventi G, Lubovich A, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009;68:1440-1446.
DOI
ScienceOn
|
85 |
Ding Y, Chen M, Liu Z, et al. atBioNet: an integrated network analysis tool for genomics and biomarker discovery. BMC Genomics 2012;13:325.
DOI
|
86 |
Pimentel-Santos FM, Ligeiro D, Matos M, et al. Whole blood transcriptional profiling in ankylosing spondylitis identifies novel candidate genes that might contribute to the inflammatory and tissue-destructive disease aspects. Arthritis Res Ther 2011;13:R57.
DOI
ScienceOn
|
87 |
Schwanhausser B, Busse D, Li N, et al. Global quantification of mammalian gene expression control. Nature 2011;473:337-342.
DOI
ScienceOn
|